Search Results - "Longenecker, B M"

Vascular Cell Adhesion Molecule-1 Expressed by Bone Marrow Stromal Cells Mediates the Binding of Hematopoietic Progenitor Cells by Simmons, Paul J., Masinovsky, Boris, Longenecker, Brian M., Berenson, Ronald, Torok-Storb, Beverly, Gallatin, William M.

“…Human bone marrow-derived CD34+ cells were analyzed for the expression of the β1-family of integrin adhesion molecules. Integrin α4β1 was consistently…”
Get full text

Expression of MUC1 mucin on activated human T cells : Implications for a role of MUC1 in normal immune regulation by AGRAWAL, B, KRANTZ, M. J, PARKER, J, LONGENECKER, B. M

“…MUC1 mucin is expressed by normal and malignant epithelial cells and is thought to function through cell-cell interactions and transmembrane signal…”
Get full text

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine by HOLMBERG, L. A, OPARIN, D. V, GOOLEY, T, LILLEBY, K, BENSINGER, W, REDDISH, M. A, MACLEAN, G. D, LONGENECKER, B. M, SANDMAIER, B. M

“…The purpose of this study was to evaluate the toxicity and potential efficacy of administering the THERATOPE STn-KLH cancer vaccine to ovarian and breast…”
Get full text

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine by MacLean, G D, Reddish, M A, Koganty, R R, Longenecker, B M

“…The humoral immune response of 85 metastatic breast, ovarian, and colorectal cancer patients was analyzed after immunization with THERATOPE STn-KLH (KLH,…”
Get more information

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide by MacLean, G D, Miles, D W, Rubens, R D, Reddish, M A, Longenecker, B M

“…THERATOPE (Biomira Inc., Edmonton, AB, Canada) STn-KLH cancer vaccine induces strong antibody titers against both the synthetic STn epitope and against a…”
Get more information

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer by MILES, D. W, TOWLSON, K. E, GRAHAM, R, REDDISH, M, LONGENECKER, B. M, TAYLOR-PAPADIMITRIOU, J, RUBENS, R. D

“…Studies in animal models of mouse mammary carcinoma have shown that ovine submaxillary mucin, which carries multiple sialyl-Tn (STn) epitopes, is effective in…”
Get full text

Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer by Moase, E H, Qi, W, Ishida, T, Gabos, Z, Longenecker, B M, Zimmermann, G L, Ding, L, Krantz, M, Allen, T M

“…The fate of breast cancer patients is dependent upon elimination or control of metastases. We studied the effect of antibody-targeted liposomes containing…”
Get full text

Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide by Reddish, Mark A., MacLean, Grant D., Koganty, R. Rao, Kan‐Mitchell, June, Jones, Vicky, Mitchell, Malcolm S., Longenecker, B. Michael

“…Sixteen metastatic breast cancer patients were immunized with a low dose (5 μg) of a 16 amino acid MUC1 peptide (GVTSAPDTRPAPGSTA) conjugated to KLH (BP16‐KLH)…”
Get full text

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy by REDDISH, M. A, MACLEAN, G. D, POPPEMA, S, BERG, A, LONGENECKER, B. M

“…Patients with metastatic breast, colorectal or ovarian cancers received active specific immunotherapy (ASI) with Theratope sialyl-Tn-KLH (keyhole limpet…”
Get full text

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine by Sandmaier, B M, Oparin, D V, Holmberg, L A, Reddish, M A, MacLean, G D, Longenecker, B M

“…Seven ovarian and 33 breast high-risk stage II/III and stage IV cancer patients received high-dose chemotherapy followed by stem cell rescue. Thirty to 151…”
Get more information

Immunogenicity and antitumor activity of a liposomal MUC1 peptide‐based vaccine by Samuel, John, Budzynski, Wladyslaw A., Reddish, Mark A., Ding, Lei, Zimmermann, Gabrielle L., Krantz, Mark J., Koganty, R. Rao, Longenecker, B. Michael

“…A human MUC1‐transfected mouse mammary adenocarcinoma cell line (GZHI) was used to develop both subcutaneous and intravenous tumor models. A vaccine…”
Get full text

Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells by RAGUPATHI, G, HOWARD, L, CAPPELLO, S, RAO KOGANTY, R, DONGXU QIU, LONGENECKER, B. M, REDDISH, M. A, LLOYD, K. O, LIVINGSTON, P. O

“…Sialyl-Tn (STn) is an O-serine- or O-threonine-linked disaccharide [NeuAcalpha(2-->6)GalNAcalpha-O-Ser/Thr) expressed on mucins of most types of adenocarcinoma…”
Get full text

MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats by KAM, J. L, REGIMBALD, L. H, HILGERS, J. H. M, HOFFMAN, P, KRANTZ, M. J, LONGENECKER, B. M, HUGH, J. C

“…We reported recently that breast cancer-associated MUC1 is a ligand for intercellular adhesion molecule-1 (ICAM-1; L. H. Regimbald et al., Cancer Res., 56:…”
Get full text

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant by MACLEAN, G. D, REDDISH, M, KOGANTY, R. R, TING WONG, SHAM GANDHI, SMOLENKSI, M, SAMUEL, J, NABHOLTZ, J. M, LONGENECKER, B. M

“…We have synthesized various formulations that have potential for active specific immunotherapy (ASI) of human cancers. Sialyl-Tn (STn) is a potentially…”
Get full text

Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes by Agrawal, B, Krantz, M J, Reddish, M A, Longenecker, B M

“…Antigen-specific MHC class II- and class I-restricted helper and cytotoxic T cell responses are important anti-cancer immune responses. MUC1 mucin is a…”
Get full text

Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate by FUNG, P. Y. S, MADEJ, M, KOGANTY, R. R, LONGENECKER, B. M

“…A synthetic tumor-associated glycoconjugate (S-TAG) "vaccine" formulation was developed for active specific immunotherapy of a murine mammary adenocarcinoma…”
Get full text

Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen by Schuman, J., Campbell, A.P., Koganty, R.R., Longenecker, B.M.

“…: MUC1 mucin is a large transmembrane glycoprotein, the extracellular domain of which is formed by a repeating 20 amino acid sequence, GVTSAPDTRPAPGSTAPPAH. In…”
Get full text

Does pregnancy immunize against breast cancer ? by AGRAWAL, B, REDDISH, M. A, KRANTZ, M. J, LONGENECKER, B. M

“…Multiparity has been linked with protection against breast cancer. T cells from biparous women, but not T cells from nulliparous women or men, specifically…”
Get full text

CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy by Yacyshyn, M B, Poppema, S, Berg, A, MacLean, G D, Reddish, M A, Meikle, A, Longenecker, B M

“…Lymphocyte activation markers CD69 and HLA-DR were studied in metastatic breast and ovarian cancer patients who received active specific immunotherapy (ASI)…”
Get more information

Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA) by FUNG, P. Y. S, LONGENECKER, B. M

“…Epiglycanin (Epi) is a mucin-like glycoprotein carrying multiple Thomsen Freidenreich (TF) and Tn determinants secreted by a murine mammary adenocarcinoma,…”
Get full text